Identification and Optimization of 4‐Anilinoquinolines as Inhibitors of Cyclin G Associated Kinase

4‐Anilinoquinolines were identified as potent and narrow‐spectrum inhibitors of the cyclin G associated kinase (GAK), an important regulator of viral and bacterial entry into host cells. Optimization of the 4‐anilino group and the 6,7‐quinoline substituents produced GAK inhibitors with nanomolar act...

Full description

Saved in:
Bibliographic Details
Published inChemMedChem Vol. 13; no. 1; pp. 48 - 66
Main Authors Asquith, Christopher R. M., Laitinen, Tuomo, Bennett, James M., Godoi, Paulo H., East, Michael P., Tizzard, Graham J., Graves, Lee M., Johnson, Gary L., Dornsife, Ronna E., Wells, Carrow I., Elkins, Jonathan M., Willson, Timothy M., Zuercher, William J.
Format Journal Article
LanguageEnglish
Published Germany 08.01.2018
Subjects
Online AccessGet full text

Cover

Loading…
Abstract 4‐Anilinoquinolines were identified as potent and narrow‐spectrum inhibitors of the cyclin G associated kinase (GAK), an important regulator of viral and bacterial entry into host cells. Optimization of the 4‐anilino group and the 6,7‐quinoline substituents produced GAK inhibitors with nanomolar activity, over 50 000‐fold selectivity relative to other members of the numb‐associated kinase (NAK) subfamily, and a compound (6,7‐dimethoxy‐N‐(3,4,5‐trimethoxyphenyl)quinolin‐4‐amine; 49) with a narrow‐spectrum kinome profile. These compounds may be useful tools to explore the therapeutic potential of GAK in prevention of a broad range of infectious and systemic diseases. Targeting GAK: The availability of chemical probes with improved selectivity for cyclin G associated kinase (GAK) or a different spectrum of off‐targets would be useful in target validation studies. Herein we report the synthesis and characterization of 4‐anilinoquinolines and 4‐anilinoquinazolines as potent narrow‐spectrum GAK inhibitors. Several of these compounds have the potential for development into high‐quality chemical probes for the study of GAK biology.
AbstractList 4‐Anilinoquinolines were identified as potent and narrow‐spectrum inhibitors of the cyclin G associated kinase (GAK), an important regulator of viral and bacterial entry into host cells. Optimization of the 4‐anilino group and the 6,7‐quinoline substituents produced GAK inhibitors with nanomolar activity, over 50 000‐fold selectivity relative to other members of the numb‐associated kinase (NAK) subfamily, and a compound (6,7‐dimethoxy‐N‐(3,4,5‐trimethoxyphenyl)quinolin‐4‐amine; 49) with a narrow‐spectrum kinome profile. These compounds may be useful tools to explore the therapeutic potential of GAK in prevention of a broad range of infectious and systemic diseases. Targeting GAK: The availability of chemical probes with improved selectivity for cyclin G associated kinase (GAK) or a different spectrum of off‐targets would be useful in target validation studies. Herein we report the synthesis and characterization of 4‐anilinoquinolines and 4‐anilinoquinazolines as potent narrow‐spectrum GAK inhibitors. Several of these compounds have the potential for development into high‐quality chemical probes for the study of GAK biology.
4-Anilinoquinolines were identified as potent and narrow-spectrum inhibitors of the cyclin G associated kinase (GAK), an important regulator of viral and bacterial entry into host cells. Optimization of the 4-anilino group and the 6,7-quinoline substituents produced GAK inhibitors with nanomolar activity, over 50 000-fold selectivity relative to other members of the numb-associated kinase (NAK) subfamily, and a compound (6,7-dimethoxy-N-(3,4,5-trimethoxyphenyl)quinolin-4-amine; 49) with a narrow-spectrum kinome profile. These compounds may be useful tools to explore the therapeutic potential of GAK in prevention of a broad range of infectious and systemic diseases.
4-Anilinoquinolines were identified as potent and narrow spectrum inhibitors of the cyclin G associated kinase (GAK), an important regulator of viral and bacterial entry into host cells. Optimization of the 4-anilino group and the 6,7-quinoline substituents produced GAK inhibitors with nanomolar activity, over 50,000-fold selectivity relative to other members of the numb-associated kinase (NAK) sub-family, and narrow activity spectra in the broader kinome. These compounds may be useful tools to explore the therapeutic potential of GAK in prevention of a broad range of infectious and systemic diseases.
Abstract 4‐Anilinoquinolines were identified as potent and narrow‐spectrum inhibitors of the cyclin G associated kinase (GAK), an important regulator of viral and bacterial entry into host cells. Optimization of the 4‐anilino group and the 6,7‐quinoline substituents produced GAK inhibitors with nanomolar activity, over 50 000‐fold selectivity relative to other members of the numb‐associated kinase (NAK) subfamily, and a compound (6,7‐dimethoxy‐ N ‐(3,4,5‐trimethoxyphenyl)quinolin‐4‐amine; 49 ) with a narrow‐spectrum kinome profile. These compounds may be useful tools to explore the therapeutic potential of GAK in prevention of a broad range of infectious and systemic diseases.
Author Graves, Lee M.
Dornsife, Ronna E.
Laitinen, Tuomo
Johnson, Gary L.
Wells, Carrow I.
Asquith, Christopher R. M.
Bennett, James M.
Godoi, Paulo H.
Tizzard, Graham J.
East, Michael P.
Zuercher, William J.
Elkins, Jonathan M.
Willson, Timothy M.
AuthorAffiliation 3 Structural Genomics Consortium and Target Discovery Institute, Nuffield Department of Clinical Medicine, University of Oxford, Old Road Campus Research Building, Oxford, OX3 7DQ, UK
1 Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
2 School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland
4 Structural Genomics Consortium, Universidade Estadual de Campinas - UNICAMP, Campinas, São Paulo, 13083-886, Brazil
5 Department of Pharmacology, University of North Carolina at Chapel Hill, NC 27599, USA
6 UK National Crystallography Service, School of Chemistry, University of Southampton, Highfield Campus, Southampton, SO17 1BJ, UK
AuthorAffiliation_xml – name: 6 UK National Crystallography Service, School of Chemistry, University of Southampton, Highfield Campus, Southampton, SO17 1BJ, UK
– name: 3 Structural Genomics Consortium and Target Discovery Institute, Nuffield Department of Clinical Medicine, University of Oxford, Old Road Campus Research Building, Oxford, OX3 7DQ, UK
– name: 1 Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
– name: 2 School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland
– name: 4 Structural Genomics Consortium, Universidade Estadual de Campinas - UNICAMP, Campinas, São Paulo, 13083-886, Brazil
– name: 5 Department of Pharmacology, University of North Carolina at Chapel Hill, NC 27599, USA
Author_xml – sequence: 1
  givenname: Christopher R. M.
  orcidid: 0000-0001-5871-3458
  surname: Asquith
  fullname: Asquith, Christopher R. M.
  organization: University of North Carolina at Chapel Hill
– sequence: 2
  givenname: Tuomo
  surname: Laitinen
  fullname: Laitinen, Tuomo
  organization: University of Eastern Finland
– sequence: 3
  givenname: James M.
  surname: Bennett
  fullname: Bennett, James M.
  organization: University of Oxford
– sequence: 4
  givenname: Paulo H.
  surname: Godoi
  fullname: Godoi, Paulo H.
  organization: Universidade Estadual de Campinas—UNICAMP
– sequence: 5
  givenname: Michael P.
  surname: East
  fullname: East, Michael P.
  organization: University of North Carolina at Chapel Hill
– sequence: 6
  givenname: Graham J.
  surname: Tizzard
  fullname: Tizzard, Graham J.
  organization: University of Southampton
– sequence: 7
  givenname: Lee M.
  surname: Graves
  fullname: Graves, Lee M.
  organization: University of North Carolina at Chapel Hill
– sequence: 8
  givenname: Gary L.
  surname: Johnson
  fullname: Johnson, Gary L.
  organization: University of North Carolina at Chapel Hill
– sequence: 9
  givenname: Ronna E.
  surname: Dornsife
  fullname: Dornsife, Ronna E.
  organization: University of North Carolina at Chapel Hill
– sequence: 10
  givenname: Carrow I.
  orcidid: 0000-0003-4799-6792
  surname: Wells
  fullname: Wells, Carrow I.
  organization: University of North Carolina at Chapel Hill
– sequence: 11
  givenname: Jonathan M.
  orcidid: 0000-0003-2858-8929
  surname: Elkins
  fullname: Elkins, Jonathan M.
  organization: Universidade Estadual de Campinas—UNICAMP
– sequence: 12
  givenname: Timothy M.
  orcidid: 0000-0003-4181-8223
  surname: Willson
  fullname: Willson, Timothy M.
  organization: University of North Carolina at Chapel Hill
– sequence: 13
  givenname: William J.
  orcidid: 0000-0002-9836-0068
  surname: Zuercher
  fullname: Zuercher, William J.
  email: william.zuercher@unc.edu
  organization: University of North Carolina at Chapel Hill
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29072804$$D View this record in MEDLINE/PubMed
BookMark eNqFkTtP5DAURi0E4t1SopTbzHAdJ47dII3CY0eAaKC2HD_Aq8SejTOgoaLZfn8jv2Q9GhiWisa-8j0-9tW3hzZ98AahIwxjDJCfqE6rcQ64AqCUbKBdzCiMKsyqzXVd8R20F-MvgKJgmG2jnZxDlTModpGdauMHZ52Sgws-k15nt7PBde5ldRBsVry9_p141zoffs_TkgoTMxmzqX90jRtCH5dYvVCp8_b65zKbxBiUk4PR2ZXzMpoDtGVlG83h-76P7i_O7-qfo-vby2k9uR6pIsdkRCrV4MKW1jQWCKZYyTyvqJKsybVmQCxvGHACinKliMalsZYzbpVmnJSE7KPTlXc2bzqjVZqtl62Y9a6T_UIE6cTXjneP4iE8iZLjAlOWBD_eBX0a1sRBdC4q07bSmzCPAvOSQsU4LRM6XqGqDzH2xq6fwSCW4YhlOGIdTrpw_P_n1vhHGgngK-DZtWbxjU7UN2f1p_wf8FOh2Q
CitedBy_id crossref_primary_10_1021_acs_jmedchem_1c00980
crossref_primary_10_1016_j_ejmech_2021_113158
crossref_primary_10_3390_molecules26237338
crossref_primary_10_3390_M1087
crossref_primary_10_3390_M1161
crossref_primary_10_3390_molecules26195911
crossref_primary_10_1021_acs_jmedchem_8b00613
crossref_primary_10_1002_ardp_201800270
crossref_primary_10_1021_acs_jmedchem_1c00302
crossref_primary_10_1016_j_celrep_2018_12_023
crossref_primary_10_1021_acs_jmedchem_9b00350
crossref_primary_10_1002_cmdc_201900428
crossref_primary_10_1002_cmdc_202000150
crossref_primary_10_1016_j_bmcl_2021_128407
crossref_primary_10_1016_j_ejmech_2024_116357
crossref_primary_10_3390_molecules29050954
crossref_primary_10_1016_j_bmc_2019_02_012
crossref_primary_10_1016_j_bmc_2019_115188
crossref_primary_10_2139_ssrn_3188329
crossref_primary_10_1002_cmdc_202200161
crossref_primary_10_1002_med_21664
crossref_primary_10_3389_fimmu_2020_01866
crossref_primary_10_3390_molecules25071697
crossref_primary_10_1016_j_bmcl_2020_127284
crossref_primary_10_1016_j_bmcl_2019_07_012
crossref_primary_10_1128_AAC_01744_19
crossref_primary_10_1016_j_bmcl_2019_05_025
crossref_primary_10_1021_acs_jmedchem_8b01213
crossref_primary_10_3390_ijms24065088
crossref_primary_10_1021_acsmedchemlett_9b00399
crossref_primary_10_1142_S273741652150054X
crossref_primary_10_1016_j_antiviral_2022_105367
crossref_primary_10_1016_j_bioorg_2018_06_003
crossref_primary_10_1016_j_molstruc_2020_128666
crossref_primary_10_1038_s41589_022_01168_3
crossref_primary_10_1002_cmdc_201900521
crossref_primary_10_3390_molecules24224016
crossref_primary_10_1038_s41598_022_15552_5
crossref_primary_10_1002_ardp_202000121
Cites_doi 10.1073/pnas.0610202104
10.1016/S0014-5793(96)01484-6
10.1158/1535-7163.MCT-10-0637
10.1038/nmeth.3398
10.1126/science.1075762
10.1371/journal.pone.0098800
10.1128/JVI.02705-14
10.1093/infdis/jir326
10.4103/0974-777X.176140
10.1021/jm400378w
10.1021/jm901877j
10.1093/hmg/ddr026
10.2174/092986711795328382
10.2302/kjm.2011-0009-OA
10.1371/journal.pone.0181585
10.1034/j.1600-0854.2002.30606.x
10.1128/JVI.00815-13
10.1083/jcb.200211018
10.1002/ijc.21469
10.1016/j.ceb.2016.01.012
10.1517/13543776.2015.1039512
10.1107/S2053273314026370
10.1038/nbt.1990
10.1517/17460441.3.6.607
10.1126/science.aaa3778
10.1021/jm501759m
10.1021/cb300610s
10.1371/journal.pone.0026034
10.1021/acs.jmedchem.6b00211
10.1016/j.str.2015.12.015
10.1021/acschembio.5b00143
10.1146/annurev-biochem-060208-104626
10.1016/j.cellsig.2013.12.023
10.1111/j.1469-1809.2010.00616.x
10.1038/nbt1068
10.1371/journal.pone.0010673
10.1371/journal.pone.0100124
10.1016/0040-4039(95)00605-C
10.1006/geno.1997.4873
10.1107/S0021889807029238
10.1074/jbc.275.2.1365
10.1016/j.tips.2015.04.005
10.3389/fnmol.2014.00057
10.1107/S2053229614024218
10.1242/jcs.052795
10.2174/092986730609220401151141
10.1107/S0021889808042726
10.1371/journal.pgen.1002794
10.1093/nar/gkv1082
10.1016/j.cell.2012.02.053
10.1007/978-1-61779-337-0_7
10.1186/1476-4598-3-21
10.1021/ja0771033
ContentType Journal Article
Copyright 2018 Wiley‐VCH Verlag GmbH & Co. KGaA, Weinheim
2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
Copyright_xml – notice: 2018 Wiley‐VCH Verlag GmbH & Co. KGaA, Weinheim
– notice: 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
5PM
DOI 10.1002/cmdc.201700663
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic

CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1860-7187
EndPage 66
ExternalDocumentID 10_1002_cmdc_201700663
29072804
CMDC201700663
Genre article
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: Wellcome Trust
  funderid: 106169/ZZ14/Z
– fundername: National Institutes of Health
  funderid: 1U24DK11604-01
– fundername: NIDDK NIH HHS
  grantid: U24 DK116204
– fundername: NIMH NIH HHS
  grantid: U01 MH104999
GroupedDBID ---
05W
0R~
1L6
1OC
29B
33P
3WU
4.4
53G
5GY
66C
6J9
77Q
8-0
8-1
A00
AAESR
AAHHS
AANLZ
AASGY
AAXRX
AAZKR
ABCUV
ABIJN
ABJNI
ABLJU
ACAHQ
ACCFJ
ACCZN
ACGFS
ACIWK
ACPOU
ACPRK
ACXBN
ACXQS
ADBBV
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFRAH
AHBTC
AHMBA
AITYG
AIURR
AIWBW
AJBDE
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMYDB
AZVAB
BDRZF
BFHJK
BMXJE
BRXPI
CS3
DCZOG
DR2
DRFUL
DRSTM
DU5
EBD
EBS
EJD
EMOBN
F5P
G-S
HBH
HGLYW
HHZ
HZ~
IX1
LATKE
LAW
LEEKS
LH4
LITHE
LOXES
LUTES
LW6
LYRES
MEWTI
MXFUL
MXSTM
MY~
O9-
OIG
P2W
P4E
PQQKQ
ROL
RWI
SUPJJ
SV3
W99
WBKPD
WOHZO
WXSBR
WYJ
XV2
YZZ
ZZTAW
~S-
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c4213-37cb14f5febf03161ca2276ca8b2dd803f9b80930c69cc3d15eff989fcd893533
IEDL.DBID DR2
ISSN 1860-7179
IngestDate Tue Sep 17 21:16:46 EDT 2024
Wed Aug 07 12:00:07 EDT 2024
Fri Aug 23 01:55:54 EDT 2024
Wed Oct 23 10:04:47 EDT 2024
Sat Aug 24 01:08:28 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords chemical probes
cyclin G associated kinase (GAK)
anilinoquinolines
antibacterial agents
Language English
License 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4213-37cb14f5febf03161ca2276ca8b2dd803f9b80930c69cc3d15eff989fcd893533
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-2858-8929
0000-0001-5871-3458
0000-0003-4181-8223
0000-0002-9836-0068
0000-0003-4799-6792
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cmdc.201700663
PMID 29072804
PQID 1956078965
PQPubID 23479
PageCount 19
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5914168
proquest_miscellaneous_1956078965
crossref_primary_10_1002_cmdc_201700663
pubmed_primary_29072804
wiley_primary_10_1002_cmdc_201700663_CMDC201700663
PublicationCentury 2000
PublicationDate January 8, 2018
PublicationDateYYYYMMDD 2018-01-08
PublicationDate_xml – month: 01
  year: 2018
  text: January 8, 2018
  day: 08
PublicationDecade 2010
PublicationPlace Germany
PublicationPlace_xml – name: Germany
PublicationTitle ChemMedChem
PublicationTitleAlternate ChemMedChem
PublicationYear 2018
References 2012; 61
2007; 104
2010; 53
2015; 36
2009; 42
1997; 44
2015; 71
1995; 36
2014; 26
2004; 3
2008; 3
2015; 348
2016; 39
2013; 8
2011; 18
2005; 23
2011; 204
2015; 89
2011; 20
2009; 122
2003; 160
2014; 57
2014; 9
2010; 5
2014; 7
2011; 29
2010; 9
2016; 44
2015; 12
2015; 58
2010; 79
2013; 87
2002; 298
2015; 10
2011; 75
2002; 3
2000; 275
2006; 118
2011; 6
2012; 149
1999; 6
2016; 59
1997; 402
2015; 25
2012; 795
2017; 12
2007; 40
2016; 8
2008; 130
2016; 24
2012; 8
e_1_2_8_28_1
e_1_2_8_47_1
e_1_2_8_24_2
e_1_2_8_49_1
e_1_2_8_26_2
e_1_2_8_3_2
e_1_2_8_7_1
e_1_2_8_5_2
e_1_2_8_9_1
e_1_2_8_66_1
e_1_2_8_20_2
e_1_2_8_22_1
e_1_2_8_45_1
e_1_2_8_64_1
e_1_2_8_43_2
e_1_2_8_62_1
e_1_2_8_1_1
e_1_2_8_41_1
e_1_2_8_60_1
e_1_2_8_17_2
e_1_2_8_19_2
e_1_2_8_36_1
e_1_2_8_59_1
e_1_2_8_13_2
e_1_2_8_34_2
e_1_2_8_15_1
e_1_2_8_38_1
e_1_2_8_57_1
Bridges A. J. (e_1_2_8_56_2) 1999; 6
e_1_2_8_32_1
e_1_2_8_30_2
e_1_2_8_55_2
e_1_2_8_11_1
e_1_2_8_53_1
e_1_2_8_51_2
e_1_2_8_27_2
e_1_2_8_29_2
e_1_2_8_23_2
e_1_2_8_25_1
e_1_2_8_46_1
e_1_2_8_48_1
e_1_2_8_2_2
e_1_2_8_4_2
e_1_2_8_6_1
e_1_2_8_8_1
e_1_2_8_21_1
e_1_2_8_42_1
e_1_2_8_44_2
e_1_2_8_65_1
e_1_2_8_63_1
e_1_2_8_40_1
e_1_2_8_61_1
e_1_2_8_16_2
e_1_2_8_18_1
e_1_2_8_39_1
e_1_2_8_12_2
e_1_2_8_35_2
e_1_2_8_14_2
e_1_2_8_37_1
e_1_2_8_58_1
e_1_2_8_54_2
e_1_2_8_10_1
e_1_2_8_31_1
e_1_2_8_52_2
e_1_2_8_33_1
e_1_2_8_50_1
References_xml – volume: 9
  start-page: 98800
  year: 2014
  publication-title: PLoS One
– volume: 40
  start-page: 786
  year: 2007
  end-page: 790
  publication-title: J. Appl. Crystallogr.
– volume: 29
  start-page: 1046
  year: 2011
  end-page: 1051
  publication-title: Nat. Biotechnol.
– volume: 42
  start-page: 339
  year: 2009
  end-page: 341
  publication-title: J. Appl. Crystallogr.
– volume: 12
  start-page: 0181585
  year: 2017
  publication-title: PLoS One
– volume: 149
  start-page: 307
  year: 2012
  end-page: 321
  publication-title: Cell
– volume: 348
  start-page: 282
  year: 2015
  end-page: 283
  publication-title: Science
– volume: 10
  start-page: 1797
  year: 2015
  end-page: 1804
  publication-title: ACS Chem. Biol.
– volume: 53
  start-page: 2892
  year: 2010
  end-page: 2901
  publication-title: J. Med. Chem.
– volume: 8
  start-page: 96
  year: 2013
  end-page: 104
  publication-title: ACS Chem. Biol.
– volume: 71
  start-page: 3
  year: 2015
  end-page: 8
  publication-title: Acta Crystallogr. Sect. A
– volume: 75
  start-page: 195
  year: 2011
  end-page: 200
  publication-title: Ann. Hum. Genet.
– volume: 87
  start-page: 8110
  year: 2013
  end-page: 8123
  publication-title: J. Virol.
– volume: 795
  start-page: 109
  year: 2012
  end-page: 118
  publication-title: Methods Mol. Biol.
– volume: 44
  start-page: 365
  year: 2016
  end-page: 371
  publication-title: Nucleic Acids Res.
– volume: 7
  start-page: 57
  year: 2014
  publication-title: Front. Mol. Neurosci.
– volume: 89
  start-page: 4387
  year: 2015
  end-page: 4404
  publication-title: J. Virol.
– volume: 8
  start-page: 1002794
  year: 2012
  publication-title: PLoS Genet.
– volume: 8
  start-page: 3
  year: 2016
  end-page: 15
  publication-title: J. Global Infect. Dis.
– volume: 118
  start-page: 1108
  year: 2006
  end-page: 1119
  publication-title: Int. J. Cancer
– volume: 298
  start-page: 1912
  year: 2002
  end-page: 1934
  publication-title: Science
– volume: 6
  start-page: 825
  year: 1999
  end-page: 843
  publication-title: Curr. Med. Chem.
– volume: 122
  start-page: 3145
  year: 2009
  end-page: 3152
  publication-title: J. Cell Sci.
– volume: 18
  start-page: 1488
  year: 2011
  end-page: 1508
  publication-title: Curr. Med. Chem.
– volume: 9
  start-page: 3342
  year: 2010
  end-page: 3350
  publication-title: Mol. Cancer Ther.
– volume: 160
  start-page: 321
  year: 2003
  end-page: 328
  publication-title: J. Cell Biol.
– volume: 130
  start-page: 2817
  year: 2008
  end-page: 2831
  publication-title: J. Am. Chem. Soc.
– volume: 3
  start-page: 428
  year: 2002
  end-page: 439
  publication-title: Traffic
– volume: 24
  start-page: 401
  year: 2016
  end-page: 411
  publication-title: Structure
– volume: 3
  start-page: 21
  year: 2004
  end-page: 27
  publication-title: Mol. Cancer Ther.
– volume: 23
  start-page: 329
  year: 2005
  end-page: 336
  publication-title: Nat. Biotechnol.
– volume: 59
  start-page: 4867
  year: 2016
  end-page: 4880
  publication-title: J. Med. Chem.
– volume: 26
  start-page: 716
  year: 2014
  end-page: 723
  publication-title: Cell. Signalling
– volume: 5
  start-page: 10673
  year: 2010
  publication-title: PLoS One
– volume: 20
  start-page: 1478
  year: 2011
  end-page: 1487
  publication-title: Hum. Mol. Genet.
– volume: 3
  start-page: 607
  year: 2008
  end-page: 621
  publication-title: Expert Opin. Drug Discovery
– volume: 204
  start-page: 957
  year: 2011
  end-page: 967
  publication-title: J. Infect. Dis.
– volume: 25
  start-page: 789
  year: 2015
  end-page: 804
  publication-title: Expert Opin. Ther. Pat.
– volume: 39
  start-page: 21
  year: 2016
  end-page: 27
  publication-title: Curr. Opin. Cell Biol.
– volume: 44
  start-page: 179
  year: 1997
  end-page: 187
  publication-title: Genomics
– volume: 104
  start-page: 808
  year: 2007
  end-page: 813
  publication-title: Proc. Natl. Acad. Sci. USA
– volume: 12
  start-page: 661
  year: 2015
  end-page: 663
  publication-title: Nat. Methods
– volume: 9
  start-page: 100124
  year: 2014
  publication-title: PLoS One
– volume: 6
  start-page: 26034
  year: 2011
  publication-title: PLoS One
– volume: 57
  start-page: 249
  year: 2014
  end-page: 277
  publication-title: J. Med. Chem.
– volume: 36
  start-page: 422
  year: 2015
  end-page: 439
  publication-title: Trends Pharmacol. Sci.
– volume: 402
  start-page: 73
  year: 1997
  end-page: 80
  publication-title: FEBS Lett.
– volume: 61
  start-page: 120
  year: 2012
  end-page: 127
  publication-title: Keio J. Med.
– volume: 36
  start-page: 3609
  year: 1995
  end-page: 3612
  publication-title: Tetrahedron Lett.
– volume: 71
  start-page: 3
  year: 2015
  end-page: 8
  publication-title: Acta Crystallogr. Sect. C
– volume: 58
  start-page: 3393
  year: 2015
  end-page: 3410
  publication-title: J. Med. Chem.
– volume: 79
  start-page: 803
  year: 2010
  end-page: 833
  publication-title: Annu. Rev. Biochem.
– volume: 275
  start-page: 1365
  year: 2000
  end-page: 1370
  publication-title: J. Biol. Chem.
– ident: e_1_2_8_44_2
  doi: 10.1073/pnas.0610202104
– ident: e_1_2_8_3_2
  doi: 10.1016/S0014-5793(96)01484-6
– ident: e_1_2_8_24_2
  doi: 10.1158/1535-7163.MCT-10-0637
– ident: e_1_2_8_64_1
  doi: 10.1038/nmeth.3398
– ident: e_1_2_8_7_1
  doi: 10.1126/science.1075762
– ident: e_1_2_8_47_1
  doi: 10.1371/journal.pone.0098800
– ident: e_1_2_8_22_1
– ident: e_1_2_8_9_1
  doi: 10.1128/JVI.02705-14
– ident: e_1_2_8_12_2
  doi: 10.1093/infdis/jir326
– ident: e_1_2_8_28_1
– ident: e_1_2_8_13_2
  doi: 10.4103/0974-777X.176140
– ident: e_1_2_8_52_2
  doi: 10.1021/jm400378w
– ident: e_1_2_8_41_1
  doi: 10.1021/jm901877j
– ident: e_1_2_8_66_1
– ident: e_1_2_8_30_2
  doi: 10.1093/hmg/ddr026
– ident: e_1_2_8_55_2
  doi: 10.2174/092986711795328382
– ident: e_1_2_8_35_2
  doi: 10.2302/kjm.2011-0009-OA
– ident: e_1_2_8_36_1
  doi: 10.1371/journal.pone.0181585
– ident: e_1_2_8_5_2
  doi: 10.1034/j.1600-0854.2002.30606.x
– ident: e_1_2_8_14_2
  doi: 10.1128/JVI.00815-13
– ident: e_1_2_8_16_2
  doi: 10.1083/jcb.200211018
– ident: e_1_2_8_18_1
– ident: e_1_2_8_15_1
– ident: e_1_2_8_21_1
  doi: 10.1002/ijc.21469
– ident: e_1_2_8_8_1
  doi: 10.1016/j.ceb.2016.01.012
– ident: e_1_2_8_54_2
  doi: 10.1517/13543776.2015.1039512
– ident: e_1_2_8_60_1
  doi: 10.1107/S2053273314026370
– ident: e_1_2_8_48_1
  doi: 10.1038/nbt.1990
– ident: e_1_2_8_49_1
  doi: 10.1517/17460441.3.6.607
– ident: e_1_2_8_20_2
  doi: 10.1126/science.aaa3778
– ident: e_1_2_8_53_1
– ident: e_1_2_8_19_2
  doi: 10.1021/jm501759m
– ident: e_1_2_8_42_1
– ident: e_1_2_8_50_1
– ident: e_1_2_8_46_1
  doi: 10.1021/cb300610s
– ident: e_1_2_8_34_2
  doi: 10.1371/journal.pone.0026034
– ident: e_1_2_8_58_1
  doi: 10.1021/acs.jmedchem.6b00211
– ident: e_1_2_8_65_1
– ident: e_1_2_8_11_1
– ident: e_1_2_8_59_1
  doi: 10.1016/j.str.2015.12.015
– ident: e_1_2_8_40_1
  doi: 10.1021/acschembio.5b00143
– ident: e_1_2_8_10_1
  doi: 10.1146/annurev-biochem-060208-104626
– ident: e_1_2_8_25_1
– ident: e_1_2_8_33_1
– ident: e_1_2_8_31_1
  doi: 10.1016/j.cellsig.2013.12.023
– ident: e_1_2_8_27_2
  doi: 10.1111/j.1469-1809.2010.00616.x
– ident: e_1_2_8_32_1
  doi: 10.1038/nbt1068
– ident: e_1_2_8_17_2
  doi: 10.1371/journal.pone.0010673
– ident: e_1_2_8_1_1
– ident: e_1_2_8_23_2
  doi: 10.1371/journal.pone.0100124
– ident: e_1_2_8_38_1
  doi: 10.1016/0040-4039(95)00605-C
– ident: e_1_2_8_4_2
  doi: 10.1006/geno.1997.4873
– ident: e_1_2_8_61_1
  doi: 10.1107/S0021889807029238
– ident: e_1_2_8_2_2
  doi: 10.1074/jbc.275.2.1365
– ident: e_1_2_8_57_1
  doi: 10.1016/j.tips.2015.04.005
– ident: e_1_2_8_26_2
  doi: 10.3389/fnmol.2014.00057
– ident: e_1_2_8_62_1
  doi: 10.1107/S2053229614024218
– ident: e_1_2_8_6_1
  doi: 10.1242/jcs.052795
– volume: 6
  start-page: 825
  year: 1999
  ident: e_1_2_8_56_2
  publication-title: Curr. Med. Chem.
  doi: 10.2174/092986730609220401151141
  contributor:
    fullname: Bridges A. J.
– ident: e_1_2_8_63_1
  doi: 10.1107/S0021889808042726
– ident: e_1_2_8_29_2
  doi: 10.1371/journal.pgen.1002794
– ident: e_1_2_8_51_2
  doi: 10.1093/nar/gkv1082
– ident: e_1_2_8_45_1
  doi: 10.1016/j.cell.2012.02.053
– ident: e_1_2_8_39_1
  doi: 10.1007/978-1-61779-337-0_7
– ident: e_1_2_8_37_1
  doi: 10.1186/1476-4598-3-21
– ident: e_1_2_8_43_2
  doi: 10.1021/ja0771033
SSID ssj0044818
Score 2.413553
Snippet 4‐Anilinoquinolines were identified as potent and narrow‐spectrum inhibitors of the cyclin G associated kinase (GAK), an important regulator of viral and...
4-Anilinoquinolines were identified as potent and narrow-spectrum inhibitors of the cyclin G associated kinase (GAK), an important regulator of viral and...
Abstract 4‐Anilinoquinolines were identified as potent and narrow‐spectrum inhibitors of the cyclin G associated kinase (GAK), an important regulator of viral...
4-Anilinoquinolines were identified as potent and narrow spectrum inhibitors of the cyclin G associated kinase (GAK), an important regulator of viral and...
SourceID pubmedcentral
proquest
crossref
pubmed
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 48
SubjectTerms Aniline Compounds - chemistry
Aniline Compounds - metabolism
Aniline Compounds - pharmacology
anilinoquinolines
antibacterial agents
Binding Sites
Catalytic Domain
chemical probes
cyclin G associated kinase (GAK)
Drug Design
Endocytosis - drug effects
Humans
Intracellular Signaling Peptides and Proteins - antagonists & inhibitors
Intracellular Signaling Peptides and Proteins - metabolism
Kinetics
Molecular Docking Simulation
Protein Binding
Protein Kinase Inhibitors - chemistry
Protein Kinase Inhibitors - metabolism
Protein Kinase Inhibitors - pharmacology
Protein Serine-Threonine Kinases - antagonists & inhibitors
Protein Serine-Threonine Kinases - metabolism
Quinazolines - chemistry
Quinazolines - metabolism
Quinazolines - pharmacology
Structure-Activity Relationship
Viruses - pathogenicity
Title Identification and Optimization of 4‐Anilinoquinolines as Inhibitors of Cyclin G Associated Kinase
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcmdc.201700663
https://www.ncbi.nlm.nih.gov/pubmed/29072804
https://www.proquest.com/docview/1956078965/abstract/
https://pubmed.ncbi.nlm.nih.gov/PMC5914168
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JT9wwFH5CnHqhpWu6ICNV9EIgsZ3EPqKhLK1oUQUStyjeRFThqcjMYXri0nt_I7-kz8kkw8ChUnuJEsWJvLzl87PfZ4D33CSFUobFOilszFEXY6VZFhsb6KmslrxdLjj5kh-d808X2cWdLP6OH2IIuAXNaO11UPBKNbsL0lB9ZQIFYeCXQ6-JRjiw6QVU9G3gj8KpRxvgS0WexDhvkT1rY0J3lz9f9koPoObDHZN3kWzrig4eQ9U3otuB8n1nOlE7-uc9fsf_aeUTWJvjVLLXCdY6rFj_FLZOO6Lr2TY5W-RtNdtki5wuKLBnz8B1-b9uHhAklTfkKxqnq3nWJxk7wm9vfu_5GquI3YCXUNeGVA059pe1qsMpQKHYaBaSN29vfh2SXpSsIZ9rj-73OZwffDwbHcXzEx1izWnK0JpplXKXOascWpM81RWlRa4roagxImFOKpFIluhcas1MmlnnpJBOG8RViExfwKofe_sKiHSUZRalTAnDEcOKvLK5zgrmOMNJJIvgQz-i5Y-OuKPsKJppGTq1HDo1gs1-wEvUrbBgUnk7njZlyKUMdPx5FsHLTgCGf1GZhJO9eATFkmgMBQJv9_IbX1-2_N2ZTBEGiwhoO_J_qV45OtkfDU-v_-WjN_AI70UbORJvYXVyPbXvEEtN1EarL38A5iwatA
link.rule.ids 230,315,786,790,891,1382,27955,27956,46327,46751
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Jb9QwFH6CcoAL-xJWI6FyadokthP7WE0pU9opFZpK3KJ4UyNUD2JmDsOpF-78xv4SnpNJhqEHJLhESuJEXt7y-dnvM8AbZpJCKUNjnRQ2ZqiLsdKUx8YGeiqrJWuWC0bH-fCUffjMu92EIRem5YfoA25BMxp7HRQ8BKR3Vqyh-twEDsJAMIdu8zrcQJ3nQTf3PvUMUjj5aEJ8qciTGGcusuNtTLKd9e_X_dIVsHl1z-TvWLZxRvt3QHXNaPegfNmez9S2_v4Hw-N_tfMu3F5CVbLbytY9uGb9fdg8abmuF1tkvErdmm6RTXKyYsFePADXpgC7ZUyQVN6Qj2ifzpeJn2TiCLu8-Lnra6wj9gNeQmWnpJqSA39WqzocBBSKDRYhf_Py4sd70kmTNeSw9uiBH8Lp_rvxYBgvD3WINctSigZNq5Q57qxyaFDyVFdZVuS6EiozRiTUSSUSSROdS62pSbl1TgrptEFoheD0EWz4ibdPgEiXUW5R0JQwDGGsyCuba15QxyjOI2kEb7shLb-23B1ly9KclaFTy75TI3jdjXiJ6hXWTCpvJ_NpGdIpAyN_ziN43EpA_69MJuFwLxZBsSYbfYFA3b3-xtdnDYU3lykiYRFB1gz9X6pXDkZ7g_7u6b989ApuDsejo_Lo4PjwGdzC56IJJInnsDH7NrcvEFrN1MtGeX4BhB8e1A
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3Lb9MwGP8EQ0JcYLwzNjASGpdlS2wnsY9Tu7IxNiq0SbtF8UuL0NJpbQ_ltAt3_sb9JXxOmnRlByS4REpiW358b_v7GeADN1GmlGGhjjIbcuTFUGmWhMZ6eCqrJa-3C46O0_1T_vksObuVxd_gQ3QBN88Ztbz2DH5p3M4CNFRfGA9B6PHlUGvehwfYNvXuV_9bByCFvkcd4YtFGoXouMgWtjGiO8v1l9XSHVvz7pHJ26ZsrYsGT6BoR9EcQfm-PZ2obf3jD4DH_xnmKjyeG6pkt6Gsp3DPVs9gc9ggXc-2yMkicWu8RTbJcIGBPXsOrkkAdvOIICkqQ76idLqYp32SkSP85vrXblViF3Ea8OH7OibFmBxU56Uq_TVAvlhv5rM3b65_fiItLVlDDssK9e8LOB3snfT2w_mVDqHmNGYozrSKuUucVQ7FSRrrgtIs1YVQ1BgRMSeViCSLdCq1ZiZOrHNSSKcNGlZomr6ElWpU2ddApKMssUhmShiORqxIC5vqJGOOM_QiWQAf2xXNLxvkjrzBaKa5n9S8m9QA3rcLniNz-R2TorKj6Tj3yZQejz9NAnjVEEDXFpWRv9qLB5AtkUZXwAN3L_-pyvMawDuRMdrBIgBar_xfupf3jvq97m3tXyq9g4fD_iD_cnB8-AYe4WdRR5HEOqxMrqZ2A-2qiXpbs85vGMAdgw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Identification+and+Optimization+of+4%E2%80%90Anilinoquinolines+as+Inhibitors+of+Cyclin%E2%80%85G+Associated+Kinase&rft.jtitle=ChemMedChem&rft.au=Asquith%2C+Christopher+R.+M.&rft.au=Laitinen%2C+Tuomo&rft.au=Bennett%2C+James+M.&rft.au=Godoi%2C+Paulo+H.&rft.date=2018-01-08&rft.issn=1860-7179&rft.eissn=1860-7187&rft.volume=13&rft.issue=1&rft.spage=48&rft.epage=66&rft_id=info:doi/10.1002%2Fcmdc.201700663&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_cmdc_201700663
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1860-7179&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1860-7179&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1860-7179&client=summon